Members Login
ACTG Network
  • Home
  • About
    • About the ACTG
    • Leadership and Organizational Matrix
    • ACTG Committees and Centers
    • Underrepresented Populations
    • Contact the LOC
  • Clinical Trials
    • About the Clinical Trials Process
    • Active Clinical Trials
    • Clinical Trials Resources
    • Study Result Slides
  • Sites
  • Community
    • Global Community Advisory Board
    • Community Resources
    • They Became My Family
  • Publications
  • News
    • In Memorium
    • Press Releases & Announcements
    • Newsletters
  • For Researchers
    • Submit a Proposal
    • Small Clinical Trials RFA –HIV Remission & Cure
    • Specimen Repository Website
    • HIV Databases

The Ponce de Leon Center CRS

Location

341 Ponce de Leon Avenue, N.E.
Atlanta, GA 30308-2012
United States of America

http://poncecrs.emory.edu/

Phone404-616-6313
CRS Coordinator

Ericka Patrick
erpatri@emory.edu
404-616-6313

CRS Leader

Carlos del Rio
cdelrio@emory.edu
404-727-1557

Studies
  • A5128: US Genomic Sampling
  • A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO)
  • A5332: REPRIEVE Trial
  • A5354: Early ART in Acute HIV
  • A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults
  • A5359: The LATITUDE Study
  • A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
  • A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors
  • A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy
  • A5377: Tri-specific Antibody
  • A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
  • A5372: Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study)
  • A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies
  • A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B

Mission

The mission of the ACTG Network
is to cure HIV and reduce the
burden of disease due to HIV
and its complications, including
tuberculosis and viral hepatitis.

Useful Links

Government Resources
Clinical Trials Resources
Grants and Contracts
New Members

© ACTG. All Rights Reserved. | admin login